Reuters logo
1 年前
BRIEF-Allergan and Adamas enter settlement with Amneal Pharmaceuticals
2016年8月31日 / 中午12点27分 / 1 年前

BRIEF-Allergan and Adamas enter settlement with Amneal Pharmaceuticals

Aug 31 (Reuters) - Allergan Plc

* Allergan and Adamas announce settlement with Amneal related to namzaric patent litigation

* Adamas will grant amneal a license to market generic versions of namzaric beginning on January 1, 2025

* Other terms of settlement were not disclosed

* Under certain circumstances, amneal has an option to launch an authorized generic version of namzaric beginning on January 1, 2026

* Settlement provides additional clarity for patent-protected life of namzaric

* Alternatively, under certain circumstances, amneal has option to launch authorized generic version of namzaric beginning on January 1, 2026 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below